Stratified effect between gene promoter region methylation and different cancer stages for cancer recurrence in patients with colorectal cancer
| Recurrence in different stages by methylation | Normal tissues | Tumor tissues | ||||||
|---|---|---|---|---|---|---|---|---|
| Number of participants | Number of cases (%) | Crude | Adjusted | Number of participants | Number of cases (%) | Crude | Adjusted | |
| OR 95% CI | OR 95% CI | OR 95% CI | OR 95% CI | |||||
| CDKN2A | ||||||||
| Unmethylation | ||||||||
| Local (1 and 2) | 55 | 7 (12.7) | 1.00 (referent) | 1.00 (referent) | 44 | 5 (11.4) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 53 | 25 (47.2) | 6.12 (2.35 to 15.97) | 5.56 (2.04 to 15.16) | 32 | 14 (43.8) | 6.07 (1.89 to 19.43) | 6.09 (1.71 to 21.70) |
| Methylation | ||||||||
| Local (1 and 2) | 15 | 1 (6.7) | 1.00 (referent) | 1.00 (referent) | 26 | 3 (11.5) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 9 | 8 (88.9) | 112.00 (6.13 to 2045.17) | 38.97 (1.26 to 1204.16) | 30 | 19 (63.3) | 13.24 (3.22 to 54.45) | 11.49 (2.47 to 53.53) |
| p Value* | 0.001 | 0.036 | <0.001 | 0.002 | ||||
| MLH1 | ||||||||
| Unmethylation | ||||||||
| Local (1 and 2) | 68 | 8 (11.8) | 1.00 (referent) | 1.00 (referent) | 57 | 7 (12.3) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 59 | 31 (52.5) | 8.30 (3.39 to 20.37) | 6.80 (2.64 to 17.54) | 54 | 29 (53.7) | 8.29 (3.19 to 21.53) | 6.88 (2.48 to 19.08) |
| Methylation | ||||||||
| Local (1 and 2) | 2 | 0 (0.0) | 1.00 (referent) | 1.00 (referent) | 13 | 1 (7.7) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 3 | 2 (66.7) | NA† | NA† | 8 | 4 (50.0) | 12.00 (1.02 to 141.34) | 21.31 (0.78 to 579.63) |
| p Value* | NA† | NA† | 0.048 | 0.070 | ||||
| MGMT | ||||||||
| Unmethylation | ||||||||
| Local (1 and 2) | 67 | 7 (10.4) | 1.00 (referent) | 1.00 (referent) | 40 | 4 (10.0) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 56 | 29 (51.8) | 9.21 (3.59 to 23.62) | 7.86 (2.89 to 21.34) | 33 | 20 (60.6) | 13.85 (3.98 to 48.18) | 11.75 (2.98 to 46.37) |
| Methylation | ||||||||
| Local (1 and 2) | 3 | 1 (33.3) | 1.00 (referent) | 1.00 (referent) | 30 | 4 (13.3) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 6 | 4 (66.7) | 4.00 (0.21 to 75.66) | NA† | 29 | 13 (44.8) | 5.28 (1.47 to 19.03) | 7.42 (1.62 to 33.91) |
| p Value* | 0.355 | NA† | 0.011 | 0.010 | ||||
| ≥1 of genes | ||||||||
| Unmethylation | ||||||||
| Local (1 and 2) | 51 | 6 (11.8) | 1.00 (referent) | 1.00 (referent) | 24 | 2 (8.3) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 47 | 21 (44.7) | 6.30 (2.25 to 17.66) | 6.13 (2.04 to 18.36) | 20 | 10 (50.0) | 11.00 (2.03 to 59.75) | 13.36 (1.73 to 103.11) |
| Methylation | ||||||||
| Local (1 and 2) | 19 | 2 (10.5) | 1.00 (referent) | 1.00 (referent) | 46 | 6 (13.0) | 1.00 (referent) | 1.00 (referent) |
| Advanced (3 and 4) | 15 | 12 (80.0) | 25.50 (4.00 to 162.38) | 17.65 (1.91 to 163.52) | 42 | 23 (54.8) | 8.07 (2.82 to 23.09) | 6.56 (2.17 to 19.83) |
| p Value* | <0.001 | 0.011 | <0.001 | 0.001 | ||||
Adjusted for gender and age at surgery (continuous).
*p for the stratified effect interaction.
†NA due to limited numbers of cases.
CDKN2A, cyclin-dependent kinase inhibitor 2A; MGMT, O-6-methylguanine DNA methyltransferase; MLH1, mutL homolog 1; NA, not available.